G
GLP1 Lawsuit
Mass Tort Case Review
Call
GLP-1 Drug Injury

Rybelsus Lawsuit

Rybelsus is Novo Nordisk's oral form of semaglutide — the same active ingredient as Ozempic and Wegovy. The same gastrointestinal and other injury claims that drive Ozempic litigation apply to Rybelsus users.

Call (717) 724-7503

Free Confidential Case Review

No fee unless you win. Takes under 60 seconds.

Why Rybelsus is included in MDL 3094

Rybelsus delivers semaglutide systemically, so it shares the same mechanism — and the same severe gastrointestinal effects — as injectable Ozempic. Plaintiffs taking Rybelsus are eligible to file in the consolidated federal litigation.

Qualifying injuries

Gastroparesis, severe pancreatitis, intestinal obstruction, gallbladder disease, vision loss (NAION), and aspiration during anesthesia are all qualifying injuries for Rybelsus users.

Frequently Asked Questions

Get your free, confidential case review

Takes under 60 seconds. No fee unless you win.

Free Confidential Case Review

No fee unless you win. Takes under 60 seconds.